SCHEMBL4089930

SCHEMBL4089930

CCOC(=O)c1ccc2cc(-c3nn(C4CCCCO4)c4ccc(C#N)cc34)ccc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38
ELANE P08246 1/20 0.37
CMKLR1 Q99788 2/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.36
HSD17B10 Q99714 1/20 0.36
EGLN1 Q9GZT9 2/20 0.36
PTGER4 P35408 2/20 0.36
SIRT2 Q8IXJ6 3/20 0.35
SIRT1 Q96EB6 3/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4084335 0.88 RXRA (0.42) RXRARXRBRXRGCMKLR1KDM2B
SCHEMBL4084834 0.87 EGLN1 (0.40) RXRARXRBRXRGEGLN1
SCHEMBL4084768 0.87 JAK2 (0.40) RXRARXRBRXRGCMKLR1EGLN1
SCHEMBL4084836 0.86 KCNH2 (0.37) RXRARXRBRXRGCMKLR1MAPT
SCHEMBL4090008 0.85 CDK1 (0.39) RXRARXRBRXRG
SCHEMBL4094652 0.83 RAB9A (0.37) RXRARXRBRXRGCMKLR1HSD17B10
SCHEMBL4080192 0.83 RXRA (0.39) RXRARXRBRXRGCMKLR1
SCHEMBL5378043 0.83 RXRA (0.38) RXRARXRBRXRGCMKLR1HSD17B10
SCHEMBL4079783 0.82 CMKLR1 (0.36) RXRARXRBRXRGCMKLR1HSD17B10
SCHEMBL4080434 0.81 RXRA (0.37) RXRARXRBRXRGCMKLR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 EP disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
EP-1692128-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS Signal Pharmaceuticals LLC (US) 2006-08-23 EP disclosed
US-20060004043-A1 Indazole compounds and methods of use thereof BHAGWAT SHRIPAD S 2006-01-05 US disclosed
WO-2005051942-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF WNT3, WNT3A, WNK3 RXRA 2265/4885RXRB 2226/4885RXRG 2156/4885
US-20060004043-A1 Indazole compounds and methods of use thereof WNT3, WNT3A, WNK3 RXRA 2170/4885RXRB 2113/4885RXRG 2042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.